BioSpace

ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer

Sac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial cancer by 6.9 months over chemotherapy in a Phase 3 trial—becoming the first TROP2-directed ADC to do so in this setting, Merck told BioSpace.

By BioSpace

1 min read
ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights